Colorectal and other GI cancers:

Indications for: CAMPTOSAR

Metastatic colorectal cancer, as 1st line therapy with 5-FU and leucovorin, or as monotherapy if disease recurs or progresses after fluorouracil-based therapy.

Adult Dosage:

Give by IV infusion over 90 mins. Combination therapy: 125mg/m2 on days 1, 8, 15, 22; or, 180mg/m2 on days 1, 15, 29; both: give every 6 weeks. Monotherapy: 125mg/m2 on days 1, 8, 15, 22, then 2-week rest; or, 350mg/m2 once every 3 weeks. Elderly (≥70yrs), pelvic or abdominal radiotherapy, performance status of 2, increased bilirubin, homozygous UGT1A1*28 allele, or toxicity: reduce initial dose. May pretreat with antiemetics and/or atropine. Dose modifications: see full labeling.

Children Dosage:

Not established.

Boxed Warning:

Diarrhea. Myelosuppression.

CAMPTOSAR Warnings/Precautions:

Not for use as part of 5-FU/LV "Mayo Clinic" regimen except in certain circumstances (see full labeling). If late diarrhea occurs, promptly treat with loperamide; suspend until bowel function normalizes. Risk of myelosuppression. Infections. Monitor blood counts; suspend if neutropenic fever or ANC <1000/mm3 occurs. Volume depleted. Renal or hepatic impairment. Dialysis: not recommended. Gilbert's syndrome or abnormal glucuronidation. Discontinue if interstitial pulmonary disease occurs. Avoid extravasation. Elderly. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 6 months after the last dose. Advise males with female partners to use condoms during and for 3 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 7 days after the last dose).

CAMPTOSAR Classification:

Topoisomerase inhibitor.

CAMPTOSAR Interactions:

Concomitant irradiation: not recommended. Concomitant CYP3A4 inducers (eg, phenytoin, phenobarbital, carbamazepine, rifampin, St. John's wort), CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole), UGT1A1 inhibitors (eg, atazanavir, gemfibrozil): not recommended. Consider non-enzyme inducing therapies at least 2 weeks prior to irinotecan initiation. Discontinue strong CYP3A4 inhibitors at least 1 week prior to initiating irinotecan. Avoid diuretics or laxatives if diarrhea occurs. May affect neuromuscular blocking agents.

Adverse Reactions:

Nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, mucositis, neutropenia, leukopenia, anemia, thrombocytopenia, asthenia, pain, fever, infection, abnormal bilirubin, alopecia, weight decrease; hypersensitivity reactions (discontinue if occurs), pulmonary toxicity.


Testing considerations: UGT1A1 mutation analysis

How Supplied:

Single-dose vial (2mL, 5mL, 15mL)—1